AKBA Akebia Therapeutics
- 1.3300
- -0.0400-2.92%
- 1.3100
- -0.0200-1.50%
Akebia Therapeutics News
Akebia Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
Analysts' Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Piper Sandler Remains a Buy on Akebia Therapeutics (AKBA)
Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position
Akebia Therapeutics Analyst Ratings
Optimistic Buy Rating for Akebia Therapeutics Amid Strategic Financial Restructuring and Anticipated FDA Approval
BTIG Remains a Buy on Akebia Therapeutics (AKBA)
BTIG Keeps Their Buy Rating on Akebia Therapeutics (AKBA)
BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4
Akebia Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
Akebia Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Akebia Therapeutics (AKBA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Akebia Therapeutics (AKBA), Teva Pharmaceutical (TEVA) and Quest Diagnostics (DGX)
Positive Prospects for Akebia Therapeutics: Buy Rating Upheld Amidst Drug Approval & Global Launch Preparations
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $3.75 Price Target
Akebia Therapeutics Analyst Ratings
Akebia Spikes as H.C. Wainwright Upgrades on Potential Vadadustat Approval
HC Wainwright & Co. Upgrades Akebia Therapeutics to Buy, Raises Price Target to $3.75
Analysis
Price Target
No Data
